The brain's transporters: a field guide
How the proteins that clear, recycle and load neurotransmitters work, what each does in brain and body, and which medicines act on them.
A neurotransmitter signal is shaped as much by how it ends as by how it starts. Receptors read the message. Transporters decide how long it lasts, how far it spreads, and whether there is enough transmitter left for the next one.
Every transporter in this post does one of four jobs:
- Clear. Pull transmitter out of the synapse so the signal stops.
- Recycle. Return it to the cell that released it, or to a neighbouring glial cell, for reuse.
- Load. Pack it into vesicles so it can be released again.
- Supply. Carry fuel and raw materials across the blood-brain barrier.
This is also where much of psychiatry's pharmacology acts. Most antidepressants, the main ADHD medications, one class of anti-seizure drug and the treatments for tardive dyskinesia all work by changing what a transporter does.
This post is one of three. The companion posts cover the neurotransmitters these transporters carry and the receptors that read them.
#How this list was prioritized
The human genome encodes more than 400 solute carrier (SLC) transporters. This post covers about 25, ranked by impact: how much of brain function depends on the transmitter, and how much clinical leverage the transporter gives us.
- Glutamate and GABA come first. They carry the large majority of fast signalling in the brain, as its main accelerator and brake.
- Serotonin, dopamine and noradrenaline come next. Few neurons use them, but they tune mood, motivation, attention and arousal across the whole brain.
- Vesicular loaders, glycine and acetylcholine follow, then a supporting cast and the blood-brain barrier supply chain.
Each transporter section is self-contained and follows the same order: what it is, how it works, what it does in the brain and body, its role in psychiatric and neurological conditions, and the drugs that act on it.
#The shared mechanics
Almost every transporter here works the same way: it borrows energy from an ion gradient to move its cargo uphill. Learn this once and each later section becomes a variation on it.
#Alternating access
A channel is an open pore. A transporter is a revolving door: it is never open to both sides of the membrane at once.
- It opens outward and binds its cargo plus one or more ions.
- It closes over them.
- It opens inward and releases them.
- It resets to face outward again.
This makes transporters far slower than channels, moving roughly one to a few hundred molecules per second each. It also lets them concentrate cargo thousands of times over, which no channel can do.
#Where the energy comes from
Transporters do not burn ATP directly. They spend gradients that pumps have already built.
- At the cell surface, the currency is sodium. The Na+/K+ pump keeps sodium high outside the cell. Plasma-membrane transporters let sodium flow in and drag transmitter along with it.
- At the vesicle, the currency is protons. A proton pump acidifies the vesicle interior. Vesicular transporters let protons flow out and swap transmitter in.
This is why energy failure, as in a stroke, is so dangerous. When the sodium gradient collapses, surface transporters stop clearing transmitter and can run backwards.
#Two locations, two jobs
| Plasma-membrane transporters | Vesicular transporters | |
|---|---|---|
| Sit on | The cell surface of neurons and glia | Synaptic vesicles inside the terminal |
| Job | Clear and recycle | Load for release |
| Driven by | Sodium, often with chloride or potassium | Protons |
| Examples | SERT, DAT, NET, EAATs, GATs | VMAT2, VGLUTs, VGAT, VAChT |
#The families
Transporters are grouped into solute carrier (SLC) families by sequence. Five families cover most of this post.
| Family | Members covered here | Carries |
|---|---|---|
| SLC1 | EAAT1 to EAAT5 | Glutamate |
| SLC6 | SERT, DAT, NET, GATs, GlyTs | Monoamines, GABA, glycine |
| SLC17 | VGLUT1 to VGLUT3 | Glutamate, into vesicles |
| SLC18 | VMAT1, VMAT2, VAChT | Monoamines and acetylcholine, into vesicles |
| SLC32 | VGAT | GABA and glycine, into vesicles |
A gene name such as SLC6A4 reads as family 6, subfamily A, member 4. That gene encodes SERT.
#Map at a glance
Every transporter in this post, in the order it appears. Rows are sorted by impact, highest first.
Transmitter leaves the vesicle, crosses the cleft, and is then taken back by the terminal or cleared by the astrocyte beside it.
| Transporter | Gene | Carries | Mainly found on | Job | Medicines that act on it |
|---|---|---|---|---|---|
| EAAT2 (GLT-1) | SLC1A2 | Glutamate | Astrocytes | Clear | None approved |
| EAAT1 (GLAST) | SLC1A3 | Glutamate | Astrocytes, cerebellar glia | Clear | None approved |
| EAAT3 | SLC1A1 | Glutamate, cysteine | Neurons | Clear, supply | None approved |
| GAT1 | SLC6A1 | GABA | GABA neuron terminals | Clear, recycle | Tiagabine |
| GAT3 | SLC6A11 | GABA | Astrocytes | Clear | None approved |
| SERT | SLC6A4 | Serotonin | Serotonin neurons, platelets, gut | Clear, recycle | SSRIs, SNRIs, tricyclics |
| DAT | SLC6A3 | Dopamine | Dopamine neurons | Clear, recycle | Methylphenidate, amphetamine salts, bupropion |
| NET | SLC6A2 | Noradrenaline, dopamine | Noradrenaline neurons | Clear, recycle | Atomoxetine, SNRIs, tricyclics, bupropion |
| VMAT2 | SLC18A2 | All monoamines | Vesicles of monoamine neurons | Load | Tetrabenazine, valbenazine, deutetrabenazine |
| VGLUT1 to 3 | SLC17A7, A6, A8 | Glutamate | Vesicles of glutamate neurons | Load | None approved |
| VGAT | SLC32A1 | GABA, glycine | Vesicles of inhibitory neurons | Load | None approved |
| GlyT1 | SLC6A9 | Glycine | Astrocytes, some glutamate terminals | Clear | None approved; phase 3 trials negative |
| GlyT2 | SLC6A5 | Glycine | Glycine neuron terminals | Recycle | None approved |
| CHT1 | SLC5A7 | Choline | Cholinergic terminals | Recycle | None approved |
| VAChT | SLC18A3 | Acetylcholine | Vesicles of cholinergic neurons | Load | None approved |
| PMAT, OCT3 | SLC29A4, SLC22A3 | Monoamines | Neurons and glia, widely | Clear, low affinity | None approved |
| ENT1 | SLC29A1 | Adenosine | Neurons and glia, widely | Clear | Dipyridamole (used outside psychiatry) |
| System xc- | SLC7A11 | Cystine in, glutamate out | Astrocytes | Exchange | N-acetylcysteine acts through it |
| GLUT1 | SLC2A1 | Glucose | Blood-brain barrier | Supply | Ketogenic diet bypasses it |
| LAT1 | SLC7A5 | Large amino acids | Blood-brain barrier | Supply | Carries levodopa, gabapentin |
#EAATs: the glutamate transporters
The excitatory amino acid transporters keep the brain's main excitatory transmitter from poisoning it. Glutamate has no enzyme that breaks it down in the synapse, so uptake is the only way the signal ends.
Transmitter: glutamate. Family: SLC1. Job: clear.
#The five subtypes
| Subtype | Other name | Mainly found on | Note |
|---|---|---|---|
| EAAT2 | GLT-1 | Astrocytes, forebrain | Does about 95% of forebrain glutamate uptake |
| EAAT1 | GLAST | Astrocytes, cerebellar Bergmann glia | Dominant in cerebellum and during development |
| EAAT3 | EAAC1 | Neurons, on cell bodies and dendrites | Also imports cysteine for antioxidant synthesis |
| EAAT4 | Cerebellar Purkinje cells | Behaves partly as a chloride channel | |
| EAAT5 | Retina | Behaves mostly as a chloride channel |
#Mechanism
Each cycle carries one glutamate into the cell with three sodium ions and one proton, then returns one potassium ion outward. Coupling to three sodium ions lets the transporter hold resting glutamate outside cells about a million times lower than inside.
The work is done mostly by astrocytes, not neurons. Astrocytes convert the glutamate to glutamine, which is inert at receptors, and hand it back to neurons to be remade into glutamate. This loop is the glutamate-glutamine cycle.
#What it does
- Ends the signal and keeps one synapse from spilling into its neighbours, which preserves precision.
- Prevents excitotoxicity. Sustained glutamate over-activates receptors and floods neurons with calcium, which kills them.
- Feeds GABA synthesis. Recycled glutamate is also the precursor for GABA.
- In the body, EAAT3 reabsorbs glutamate and aspartate in the kidney and gut.
#When it goes wrong
- Stroke and energy failure. When the sodium gradient collapses, EAATs stall and then reverse, releasing glutamate. This is a main driver of damage after ischaemia.
- ALS. Loss of EAAT2 is found in the motor cortex and spinal cord of many patients. Riluzole, the first approved ALS drug, reduces glutamate signalling.
- Epilepsy. Mice without EAAT2 die of seizures. Reduced astrocyte uptake is reported in human epileptic tissue.
- Episodic ataxia type 6. Caused by mutations in the EAAT1 gene.
- Psychiatry. Altered glial glutamate transporter expression is reported in depression, schizophrenia and addiction. Variants in the EAAT3 gene have been linked to OCD. These findings are associations, not established causes.
#Drugs
No approved medicine targets an EAAT directly. The antibiotic ceftriaxone raises EAAT2 expression in animals, but it failed in the final stage of a large ALS trial in 2014. Raising EAAT2 activity remains an active research goal.
#GATs: the GABA transporters
The GABA transporters set the strength and duration of inhibition, the brain's main brake. They control both the brief inhibition at synapses and the steady background inhibition around them.
Transmitter: GABA. Family: SLC6. Job: clear and recycle.
#The four subtypes
| Subtype | Gene | Mainly found on | Note |
|---|---|---|---|
| GAT1 | SLC6A1 | Terminals of GABA neurons, some astrocytes | The main brain GABA transporter |
| GAT3 | SLC6A11 | Astrocytes | Controls GABA levels outside the synapse |
| GAT2 | SLC6A13 | Meninges, liver, kidney | Minor role in brain tissue |
| BGT1 | SLC6A12 | Kidney, liver, low levels in brain | Also carries betaine, used for cell volume control |
#Mechanism
Each cycle carries one GABA into the cell with two sodium ions and one chloride ion. GAT1 returns GABA to the terminal that released it, where it is reloaded into vesicles. GABA taken up by astrocytes through GAT3 is broken down by GABA transaminase.
#What it does
- Shapes phasic inhibition. GAT1 limits how long each inhibitory pulse lasts at the synapse.
- Sets tonic inhibition. GAT1 and GAT3 fix the low background GABA level that acts on receptors outside synapses. This sets how excitable a whole circuit is.
- Keeps rhythms in time. Fast inhibitory timing underlies the gamma oscillations linked to attention and working memory.
#When it goes wrong
- SLC6A1 disorders. Loss of one working copy of the GAT1 gene causes epilepsy with myoclonic-atonic seizures, developmental delay and often autism.
- Absence seizures. In animal models, reduced GAT1 function in the thalamus raises tonic inhibition and produces absence seizures. Too much inhibition in the wrong place can cause seizures too.
- Anxiety and sleep. Both depend on GABA tone, which is why GAT1 has been studied as a target for each.
#Drugs
- Tiagabine selectively blocks GAT1 and raises synaptic GABA. It is approved as add-on treatment for focal seizures.
- A caution worth knowing. Tiagabine has triggered seizures in people without epilepsy when used off-label. This fits the absence-seizure finding above.
- Vigabatrin is not a transporter drug, but it is the useful contrast. It raises GABA by blocking its breakdown instead of its uptake.
#SERT: the serotonin transporter
SERT is the most commonly targeted protein in psychiatric prescribing. One transporter, made from one gene, clears serotonin in the brain, the gut and the blood.
Transmitter: serotonin (5-HT). Gene: SLC6A4. Family: SLC6. Job: clear and recycle.
#Where it sits
- Brain. On serotonin neurons, whose cell bodies lie in the raphe nuclei of the brainstem and project almost everywhere. SERT sits around the synapse, not inside it, so serotonin spreads before it is cleared.
- Gut. About 95% of the body's serotonin is made in the gut wall. SERT on the gut lining clears it after it has triggered motility and secretion.
- Platelets. Platelets cannot make serotonin. They collect it from blood through SERT and release it during clotting.
#Mechanism
Each cycle carries one serotonin into the cell with one sodium ion and one chloride ion, then returns one potassium ion outward. Recovered serotonin is reloaded into vesicles by VMAT2 or broken down by monoamine oxidase.
#What it does
SERT sets the level and reach of serotonin signalling. In the brain, serotonin tunes mood, anxiety, impulse control, sleep, appetite and pain. In the body, it governs gut motility, platelet clotting and blood vessel tone.
#Drugs
| Class | Examples | Blocks |
|---|---|---|
| SSRIs | Sertraline, escitalopram, fluoxetine | SERT |
| SNRIs | Venlafaxine, duloxetine | SERT and NET |
| Tricyclics | Clomipramine, amitriptyline | SERT and NET, plus several receptors |
These are used for depression, anxiety disorders, OCD, PTSD and bulimia. Three facts explain most of what patients experience:
- Blockade is fast, benefit is slow. Standard doses occupy about 80% of SERT within hours. Improvement takes two to six weeks, so the benefit comes from slower adaptation downstream, not from raised serotonin itself.
- Side effects follow the body map. Nausea and loose stools come from gut SERT. A small rise in bleeding risk comes from platelets running low on serotonin.
- Combining serotonin-raising drugs is dangerous. Pairing a SERT blocker with a monoamine oxidase inhibitor can cause serotonin syndrome.
#When it goes wrong
- Depression and anxiety. SERT blockers work, but low serotonin as the cause of depression is not supported by current evidence. The treatment working does not prove the deficiency.
- The 5-HTTLPR story. A common variant in the SERT gene's promoter was once thought to make people vulnerable to depression after stress. Large later studies did not confirm it.
- OCD. It responds to SERT blockers specifically, often at higher doses and after longer delays than depression.
- Irritable bowel syndrome. Altered gut SERT expression has been reported, consistent with serotonin's role in motility.
#DAT: the dopamine transporter
DAT decides how long a dopamine signal lasts in the striatum, the brain's hub for movement, motivation and learning from reward. In mice bred without it, released dopamine lingers at least 100 times longer, and the animals are markedly hyperactive.
Transmitter: dopamine. Gene: SLC6A3. Family: SLC6. Job: clear and recycle.
#Where it sits
DAT is found only on dopamine neurons. Its density differs sharply by region, and this explains a lot.
| Region | DAT density | Dopamine is cleared mainly by | Function |
|---|---|---|---|
| Dorsal striatum | Very high | DAT | Movement, habits |
| Ventral striatum (nucleus accumbens) | High | DAT | Motivation, reward learning |
| Prefrontal cortex | Very low | NET and the enzyme COMT | Working memory, attention |
#Mechanism
Each cycle carries one dopamine into the cell with two sodium ions and one chloride ion. Like SERT, DAT sits beside the synapse, so dopamine diffuses and acts on nearby cells before it is recovered.
#What it does
- Times the reward signal. Brief bursts of dopamine mark outcomes that were better than expected. DAT keeps these bursts brief, so they stay informative.
- Sets movement tone. Steady striatal dopamine permits smooth, willed movement.
- Recycles. Most released dopamine is reused, not newly made, so DAT also maintains the supply.
#Drugs
- Methylphenidate blocks DAT and NET. It is a first-line ADHD treatment.
- Amphetamine-based ADHD medicines act on DAT, NET and VMAT2 to raise dopamine and noradrenaline.
- Bupropion weakly blocks DAT and NET. It is used for depression and smoking cessation.
- Modafinil weakly blocks DAT and promotes wakefulness.
How quickly a drug occupies DAT matters as much as how fully. Slow, steady occupancy gives therapeutic effect with lower misuse risk, which is why long-acting formulations are preferred.
#When it goes wrong
- ADHD. Medicines acting on DAT are among the most effective in psychiatry. Whether DAT itself is abnormal in ADHD remains unsettled, as imaging studies conflict.
- Parkinson's disease. Dopamine terminals die and take their DAT with them. The DaTscan measures striatal DAT to tell Parkinsonian syndromes from essential tremor.
- DAT deficiency syndrome. Loss of both gene copies causes a rare infant-onset movement disorder with parkinsonism and dystonia.
- Addiction. Substances with misuse potential share one effect: a fast, large rise in striatal dopamine. DAT is one of the main routes to it.
#NET: the noradrenaline transporter
NET clears noradrenaline in the brain and at sympathetic nerve endings throughout the body. It also clears most of the dopamine in the prefrontal cortex, which makes it a quiet second dopamine transporter.
Transmitters: noradrenaline, and dopamine in the prefrontal cortex. Gene: SLC6A2. Family: SLC6. Job: clear and recycle.
#Where it sits
- Brain. On noradrenaline neurons. Most arise from the locus coeruleus, a small brainstem nucleus that projects to nearly the whole brain.
- Body. On sympathetic nerve endings in the heart, blood vessels and other organs. There it recovers most of the noradrenaline those nerves release.
#Mechanism
Each cycle carries one noradrenaline into the cell with one sodium ion and one chloride ion. NET binds dopamine at least as well as noradrenaline. Because the prefrontal cortex has little DAT, NET does the dopamine clearing there.
#What it does
- Arousal and attention. Noradrenaline raises alertness and sharpens the brain's response to what matters. NET keeps that signal in its useful middle range.
- Prefrontal function. Working memory depends on moderate levels of both noradrenaline and dopamine. Too little or too much impairs it.
- Stress response. The locus coeruleus fires hard under threat, driving vigilance.
- Pain control. Noradrenaline pathways descending to the spinal cord dampen incoming pain signals.
- Cardiovascular tone. NET limits how strongly sympathetic nerves drive heart rate and blood pressure.
#Drugs
| Drug | Blocks | Used for |
|---|---|---|
| Atomoxetine, viloxazine | NET | ADHD, as non-stimulant options |
| Venlafaxine, duloxetine | SERT and NET | Depression, anxiety, nerve pain |
| Nortriptyline, desipramine | Mostly NET | Depression, nerve pain |
| Methylphenidate, bupropion | DAT and NET | ADHD; depression |
Two consequences follow from the map above. NET blockers help ADHD by raising prefrontal dopamine and noradrenaline without acting much on the striatum. They also tend to raise heart rate and blood pressure, because NET in the body is blocked too.
#When it goes wrong
- ADHD. NET blockade improves attention and impulse control, which supports a prefrontal catecholamine account of the condition.
- Depression and chronic pain. Adding NET blockade to SERT blockade helps pain conditions in a way SERT blockade alone usually does not.
- Orthostatic intolerance. A rare inherited NET mutation causes a racing heart on standing. It was the first transporter mutation tied to a human autonomic disorder.
- Hyperarousal states. Excess noradrenaline signalling is implicated in the vigilance and sleep disturbance of PTSD.
#VMAT2: the vesicular monoamine transporter
VMAT2 is the single loader for every monoamine in the brain. Dopamine, noradrenaline, serotonin and histamine neurons all depend on it to fill their vesicles, so one drug acting here changes all four systems at once.
Transmitters: dopamine, noradrenaline, serotonin, histamine. Gene: SLC18A2. Family: SLC18. Job: load.
#Where it sits
On the membrane of synaptic vesicles inside monoamine neurons. Its sibling VMAT1 does the same job outside the brain, in the adrenal gland and gut hormone cells.
#Mechanism
A proton pump first acidifies the vesicle. VMAT2 then lets two protons out for each monoamine it brings in. This concentrates transmitter inside the vesicle about 10,000 times over the surrounding cell fluid.
#What it does
- Sets the size of each signal. How full a vesicle is determines how much transmitter each release delivers.
- Protects the neuron. Dopamine left loose in the cell oxidizes into reactive, damaging products. Packing it away is a form of detoxification.
#Drugs
Blocking VMAT2 leaves vesicles underfilled, so each release delivers less. This turns monoamine signalling down without blocking any receptor.
| Drug | Used for | Note |
|---|---|---|
| Tetrabenazine | Chorea in Huntington's disease | Reversible, short-acting |
| Deutetrabenazine | Huntington's chorea, tardive dyskinesia | Longer-acting form of tetrabenazine |
| Valbenazine | Tardive dyskinesia, Huntington's chorea | Once daily |
| Reserpine | Historically, high blood pressure and psychosis | Irreversible; now rarely used |
The main risks follow directly from the mechanism: low mood, sedation and parkinsonism. These drugs carry warnings about depression and suicidal thoughts in Huntington's disease.
#When it goes wrong
- Tardive dyskinesia. Long-term dopamine receptor blockade can produce involuntary movements. Reducing dopamine release with a VMAT2 inhibitor was the first approach to win regulatory approval for it.
- Parkinson's disease. Lower VMAT2 activity leaves more loose dopamine in the cell. This may be one reason dopamine neurons are unusually fragile.
- A piece of history. Some patients on reserpine became depressed in the 1950s. That observation helped launch the monoamine theory of depression, though later analyses found the link weaker than first reported.
- Rare genetic disease. Loss of VMAT2 function causes an infant-onset disorder of movement, mood and autonomic control.
#VGLUTs and VGAT: the loaders that define a neuron
A neuron is excitatory or inhibitory because of which vesicular transporter it makes. Glutamate is present in every cell as a basic metabolite. Only cells with a VGLUT can release it as a signal.
Transmitters: glutamate (VGLUTs); GABA and glycine (VGAT). Families: SLC17 and SLC32. Job: load.
#The subtypes
| Transporter | Gene | Mainly found in | Note |
|---|---|---|---|
| VGLUT1 | SLC17A7 | Cortex, hippocampus, cerebellar cortex | The loader for most cortical excitatory synapses |
| VGLUT2 | SLC17A6 | Thalamus, brainstem, hypothalamus | The loader for most subcortical excitatory synapses |
| VGLUT3 | SLC17A8 | Scattered serotonin, acetylcholine and GABA neurons; inner ear hair cells | Lets non-glutamate neurons also release glutamate |
| VGAT | SLC32A1 | All GABA and glycine neurons | One loader for both inhibitory transmitters |
#Mechanism
Both types run on the vesicle's proton gradient. That gradient has two parts: a chemical part (acidity) and an electrical part (positive charge inside). VGLUTs draw mainly on the electrical part to pull in negatively charged glutamate. VGAT uses both.
#What they do
- Assign identity. Researchers label a neuron excitatory or inhibitory by staining for VGLUT or VGAT.
- Set signal size. The number of transporters per vesicle influences how much transmitter each vesicle holds.
- Enable co-release. VGLUT3 lets some serotonin and acetylcholine neurons send a fast glutamate signal alongside their slower one. VGAT lets some spinal neurons release GABA and glycine together.
#When they go wrong
- Deafness. A VGLUT3 mutation causes a form of inherited progressive hearing loss, because inner ear hair cells use it to signal sound.
- Epilepsy. Variants in the VGAT gene have been linked to inherited epilepsy with febrile seizures.
- Loss is not survivable. Mice lacking VGLUT1, VGLUT2 or VGAT die before or soon after birth, which shows how basic these loaders are.
#Drugs
No approved medicine targets these transporters. They are too widespread and too essential for a blocker to be selective.
#GlyT1 and GlyT2: the glycine transporters
Glycine has two opposite roles, and each has its own transporter. In the spinal cord and brainstem it is an inhibitory transmitter. In the forebrain it is a required helper for the NMDA glutamate receptor, which drives learning.
Transmitter: glycine. Genes: SLC6A9 (GlyT1), SLC6A5 (GlyT2). Family: SLC6. Job: clear (GlyT1), recycle (GlyT2).
#The two subtypes
| GlyT1 | GlyT2 | |
|---|---|---|
| Mainly found on | Astrocytes, and near glutamate synapses | Terminals of glycine neurons |
| Region | Throughout the brain and spinal cord | Spinal cord, brainstem, cerebellum |
| Ions per glycine | 2 sodium, 1 chloride | 3 sodium, 1 chloride |
| Main role | Keeps glycine low around NMDA receptors and ends inhibitory signals | Refills the terminal so vesicles can be reloaded |
#Mechanism
Both work like the other SLC6 transporters. The extra sodium ion gives GlyT2 more concentrating power, which it needs to stock glycine terminals to very high levels.
#What they do
- Inhibition in the spinal cord and brainstem. Glycine restrains motor neurons and gates sensory input, including pain and startle reflexes.
- Tuning NMDA receptors. An NMDA receptor opens only when glutamate and a co-agonist, glycine or D-serine, are both bound. By holding glycine low, GlyT1 sets how readily these receptors respond.
#When it goes wrong
- Startle disease (hyperekplexia). GlyT2 mutations leave glycine terminals underfilled. Infants show stiffness and an exaggerated startle to sound or touch.
- GlyT1 encephalopathy. Loss of GlyT1 causes a severe infant disorder with low muscle tone and breathing difficulty.
- Schizophrenia. Reduced NMDA receptor function is a leading model for its cognitive and negative symptoms. Blocking GlyT1 should raise glycine and boost those receptors.
#Drugs
The schizophrenia idea has been tested twice at scale and has not held up so far. Bitopertin failed phase 3 trials for negative symptoms. Iclepertin failed phase 3 trials for cognitive symptoms.
Bitopertin is now being developed for a blood disorder, erythropoietic protoporphyria, because red blood cell precursors also need GlyT1 to import glycine for haem synthesis. In February 2026 the FDA declined to approve it for that use until phase 3 results are in. No GlyT2 drug is approved, though GlyT2 blockers are studied for chronic pain.
#CHT1 and VAChT: the acetylcholine supply line
Acetylcholine is the exception to the reuptake rule. Its signal is ended by an enzyme, not a transporter, and what the neuron takes back is a fragment: choline.
Transmitter: acetylcholine. Genes: SLC5A7 (CHT1), SLC18A3 (VAChT). Jobs: recycle (CHT1), load (VAChT).
#The cycle
- Acetylcholine is released and acts on its receptors.
- The enzyme acetylcholinesterase splits it into choline and acetate within milliseconds.
- CHT1 carries the choline back into the terminal, driven by sodium.
- The enzyme ChAT rebuilds acetylcholine from choline.
- VAChT loads it into vesicles, driven by protons.
Step 3 is the bottleneck. Choline uptake by CHT1 sets the maximum rate at which a neuron can keep making acetylcholine. Under heavy firing, terminals move more CHT1 to the surface to keep up.
#What it does
- In the brain. Acetylcholine from the basal forebrain supports attention and the encoding of new memories. Brainstem acetylcholine helps drive REM sleep.
- In the body. It is the transmitter at every nerve-to-muscle junction and throughout the parasympathetic system.
#When it goes wrong
- Congenital myasthenic syndromes. Mutations in either CHT1 or VAChT cause inherited muscle weakness that worsens with effort, sometimes with dangerous pauses in breathing in infancy.
- Alzheimer's disease. Basal forebrain cholinergic neurons degenerate early. Imaging agents that bind VAChT are used in research to measure that loss.
#Drugs
No approved medicine targets CHT1 or VAChT. Cholinergic drugs act elsewhere in the cycle. Donepezil and related Alzheimer's drugs block the enzyme in step 2, so each released acetylcholine molecule lasts longer.
#The supporting cast
Four smaller systems fill gaps the main transporters leave. Each gets a short entry, because each explains something the headline transporters cannot.
#Uptake-2: PMAT and OCT3
Carries: serotonin, dopamine, noradrenaline, histamine. Genes: SLC29A4 (PMAT), SLC22A3 (OCT3).
SERT, DAT and NET bind tightly but saturate quickly. PMAT and OCT3 bind loosely but have large capacity, and they do not need sodium. They sit widely on neurons and glia and mop up monoamines that escape the main transporters.
- Why it matters. In animals, uptake-2 keeps clearing serotonin when SERT is blocked. This may be one reason SSRIs help some people only partly.
- Stress link. OCT3 is inhibited by the stress hormone corticosterone, a possible route by which stress alters monoamine signalling.
#ENT1 and adenosine
Carries: adenosine. Gene: SLC29A1.
Adenosine builds up as cells spend energy and acts as the brain's fatigue signal. Its accumulation during waking creates sleep pressure. ENT1 is an equilibrative transporter: it uses no ion gradient and simply moves adenosine down its concentration gradient, in either direction.
- Caffeine works on this system at the receptor, not the transporter. It blocks adenosine receptors.
- Alcohol inhibits ENT1, which raises adenosine and contributes to its sedating effect.
#System xc-: the cystine-glutamate exchanger
Carries: cystine in, glutamate out. Gene: SLC7A11.
This astrocyte exchanger swaps one glutamate out of the cell for one cystine in. It does two things at once.
- Antioxidant supply. Cystine is the limiting ingredient for glutathione, the brain's main antioxidant.
- Background glutamate. The glutamate it releases sets the low resting level outside synapses, which restrains further release through presynaptic receptors.
N-acetylcysteine feeds this exchanger. It has been tested in addiction, OCD-related conditions and other disorders, with mixed results.
#SNATs: the glutamine shuttle
Carries: glutamine. Genes: SLC38 family.
These transporters complete the glutamate-glutamine cycle from section 1. SNAT3 and SNAT5 release glutamine from astrocytes. SNAT1 and SNAT2 take it up into neurons, where it is turned back into glutamate or GABA. Without this shuttle, neurons would run out of both transmitters.
#The supply chain at the blood-brain barrier
The blood-brain barrier is a wall of tightly sealed cells lining the brain's blood vessels. Almost nothing water-soluble crosses it unaided, so the brain's fuel and the raw materials for its transmitters must be carried in.
| Transporter | Gene | Carries | Why it matters |
|---|---|---|---|
| GLUT1 | SLC2A1 | Glucose | The brain's main fuel line |
| LAT1 | SLC7A5 | Large neutral amino acids | Brings in the precursors of serotonin, dopamine and noradrenaline |
| MCT1 | SLC16A1 | Lactate, ketone bodies | The backup fuel line |
| P-glycoprotein | ABCB1 | Many drugs, outward | Pumps foreign compounds back into the blood |
#GLUT1: glucose
The brain is about 2% of body weight and uses about 20% of the body's glucose. GLUT1 carries that glucose across the barrier by facilitated diffusion, with no ion coupling. Neurons then take it up through GLUT3.
GLUT1 deficiency syndrome shows what happens when supply falls short: infant seizures, developmental delay and movement problems. The treatment is a ketogenic diet, which supplies ketone bodies that enter through MCT1 instead.
#LAT1: amino acid precursors
LAT1 carries tryptophan (for serotonin), tyrosine and phenylalanine (for dopamine and noradrenaline), and several other amino acids. They all compete for the same transporter. That competition has practical consequences.
- Levodopa and meals. The Parkinson's drug levodopa enters the brain through LAT1. A high-protein meal can crowd it out and blunt the dose.
- Phenylketonuria. Very high blood phenylalanine saturates LAT1 and starves the brain of other amino acids.
- Drug delivery. Gabapentin and pregabalin also ride LAT1 into the brain.
- Development. Rare LAT1 mutations cause autism with microcephaly.
#MCT1 and MCT2: lactate and ketones
MCT1 at the barrier and on astrocytes, and MCT2 on neurons, carry lactate and ketone bodies with a proton. They matter most during fasting, in infancy and on a ketogenic diet. Whether astrocytes routinely feed lactate to active neurons is still debated.
#P-glycoprotein: the bouncer
P-glycoprotein is not an SLC transporter. It is an ATP-powered pump that faces the blood and ejects a wide range of compounds. It is a major reason many drugs never reach the brain. Newer antihistamines such as fexofenadine cause little drowsiness partly because P-glycoprotein keeps them out.
#Patterns worth remembering
Six rules summarize the whole post. Each one lets you predict something about a transporter you have not studied.
- Termination defines the signal. How a transmitter is cleared sets how long it lasts and how far it spreads. Fast, tight clearance gives precise point-to-point signals. Slow, loose clearance gives broad, mood-like ones.
- Glia clear the fast transmitters; neurons recycle the slow ones. Astrocytes handle most glutamate and much GABA. Monoamine neurons take back their own transmitter.
- Location predicts effect. DAT is dense in the striatum and sparse in the prefrontal cortex. That one fact explains why DAT and NET drugs feel and act differently.
- The body map predicts side effects. SERT in gut and platelets, NET on the heart, VMAT2 in every monoamine neuron. A drug acts wherever its transporter is.
- Blockade is fast, benefit is slow. Transporters are occupied within hours. Clinical change often takes weeks, because the brain adapts to the new signal level.
- Gradients can fail. Transporters run on ion gradients. When energy supply collapses, they stall or reverse, and clearance becomes release.
#Two levers, opposite directions
| Lever | Effect on signalling | Example |
|---|---|---|
| Block a surface transporter | Raises it: transmitter stays in the synapse longer | SSRIs on SERT |
| Block a vesicular transporter | Lowers it: each release delivers less | Valbenazine on VMAT2 |
#Cheat sheet by condition
| Condition | Transporter targeted | Typical medicines |
|---|---|---|
| Depression, anxiety disorders | SERT, sometimes with NET | SSRIs, SNRIs |
| OCD | SERT | SSRIs at higher doses, clomipramine |
| ADHD | DAT and NET, or NET alone | Methylphenidate, amphetamine salts; atomoxetine |
| Nerve pain | SERT and NET | Duloxetine, nortriptyline |
| Focal epilepsy | GAT1 | Tiagabine |
| Tardive dyskinesia, Huntington's chorea | VMAT2 | Valbenazine, deutetrabenazine |
| Smoking cessation | DAT and NET | Bupropion |
This table describes mechanisms. It is not treatment guidance.
#What this post leaves out
This is a foundation, not a full catalogue. Four limits are worth stating plainly.
- Coverage. About 25 of more than 400 SLC transporters appear here. Left out are the transporters for taurine, creatine, proline, D-serine, zinc and thyroid hormone, along with most ion exchangers.
- Medicines only. The monoamine sections cover approved medicines. Non-medical drug use is outside the scope of this post.
- Associations are not causes. Most links between a transporter and a psychiatric condition come from genetic association, post-mortem tissue or imaging. The rare single-gene disorders are the firm evidence.
- Animal data. Several mechanisms here, such as uptake-2 limiting SSRI response, are shown in rodents and not yet confirmed in people.
Nothing here is medical advice.
#Sources
The claims below were checked against these sources on 16 November 2026. Each page was opened and the claim matched to its text.
| Claim | Source |
|---|---|
| Glutamate transporters, general | Danbolt, Prog Neurobiol 2001 |
| SLC6 family: SERT, DAT, NET, GATs, GlyTs | Kristensen et al., Pharmacol Rev 2011 |
| Ion ratios for every transporter | IUPHAR Concise Guide to Pharmacology 2019/20: Transporters |
| EAAT2 does about 95% of forebrain uptake | Petr et al., J Neurosci 2015 |
| More than 400 SLC transporters | Pizzagalli et al., FEBS J 2021 |
| SERT structure and SSRI binding | Coleman, Green and Gouaux, Nature 2016 |
| SERT occupancy of about 80% at clinical doses | Meyer et al., Am J Psychiatry 2004 |
| Serotonin and depression evidence | Moncrieff et al., Mol Psychiatry 2023 |
| Candidate genes for depression not replicated | Border et al., Am J Psychiatry 2019 |
| About 95% of serotonin is made in the gut | Koopman et al., Int J Mol Sci 2021 |
| DAT knockout mice | Giros et al., Nature 1996 |
| NET clears dopamine in frontal cortex | Morón et al., J Neurosci 2002 |
| VMAT2, general | Eiden and Weihe, Ann N Y Acad Sci 2011 |
| Brain uses about 20% of glucose | Mergenthaler et al., Trends Neurosci 2013 |
| Ceftriaxone in ALS | Cudkowicz et al., Lancet Neurol 2014 |
| Bitopertin in schizophrenia | Bugarski-Kirola et al., Biol Psychiatry 2017 |
| Bitopertin FDA decision, February 2026 | HCPLive report |
| Iclepertin in schizophrenia | Keefe et al., Lancet Psychiatry 2025 |
| Valbenazine uses and warning | FDA label |
| Deutetrabenazine uses and warning | FDA label |
| Tetrabenazine use and warning | FDA label |
| Viloxazine for ADHD | FDA label |
| Tiagabine use and seizure warning | FDA label |
| GAT1 gene and epilepsy | Carvill et al., AJHG 2015 |
| VGAT gene and epilepsy | Heron et al., Neurology 2021 |
| LAT1 gene and autism with microcephaly | Tărlungeanu et al., Cell 2016 |
| VGLUT3 gene and hearing loss | Ruel et al., AJHG 2008 |
| CHT1 gene and myasthenic syndrome | Bauché et al., AJHG 2016 |
| VAChT gene and myasthenic syndrome | O'Grady et al., Neurology 2016 |
| GlyT2 gene and startle disease | Rees et al., Nat Genet 2006 |
| GlyT1 gene and encephalopathy | Kurolap et al., AJHG 2016 |
| EAAT1 gene and episodic ataxia | Jen et al., Neurology 2005 |
| NET gene and orthostatic intolerance | Shannon et al., NEJM 2000 |
| DAT gene and infant parkinsonism-dystonia | Kurian et al., JCI 2009 |
| GLUT1 deficiency and ketogenic diet | Klepper et al., Epilepsia Open 2020 |
#Not individually sourced
These statements are standard textbook material but were not matched to an opened source.
- Concentration figures: glutamate held a million times lower outside cells; vesicles concentrating monoamines 10,000 times
- Uptake-2 limiting SSRI response in animals, and OCT3 inhibition by corticosterone
- Alcohol inhibiting ENT1; N-acetylcysteine acting through system xc-
- Levodopa competing with dietary protein at LAT1; fexofenadine kept out by P-glycoprotein
- The reserpine and depression history
- Tiagabine described as selective for GAT1 (the label names only the GABA uptake carrier)